Dr. Fred Saad is the Quebec Cancer Consortium’s project leader at the Centre hospitalier de l’Université de Montréal (CHUM). He is Professor and Chairman of Urology and Director of Genito-Urinary (G-U) Oncology at the CHUM.
Dr. Saad holds the Raymond Garneau Chair in Prostate Cancer Research and is Director of clinical research and the molecular oncology research laboratory in prostate cancer. He has held several leadership positions such as President of the Canadian Urologic Association and Chair of the National Cancer Institute of Canada G-U Group and the Canadian Uro-Oncology Group. Over the last 20 years, Dr. Saad played a leadership role and is a co-author on many of the practice-changing clinical trials and publications in advanced prostate cancer.
He presently sits on 7 steering committees of ongoing international clinical trials and serves on several guideline committees. He is a member of several editorial boards, including Lancet Oncology, JAMA Oncology, Nature Urology. He has published over 600 peer-reviewed articles, has an h-factor of over 120 and, with over 70,000 citations, is listed as one of the world’s most cited clinician-scientists.
Dr. Saad’s research interests include novel therapeutics in prostate cancer, molecular prognostic markers and mechanisms of progression.. He has over 40 ongoing clinical and basic research projects and has received over 40 million dollars in research grants. His numerous awards include the lifetime achievement award from the CHUM Research Center, Lifetime Achievement Award from the Quebec Urologic Association and in 2018 was named a Knight of The National Order of Quebec, the highest honor given by the Quebec government.
